For many pregnant women, “morning sickness” is a fleeting discomfort of the first trimester. However, for approximately 2% of gestations, this symptom evolves into a debilitating medical condition known as hyperemesis gravídica (HG). This severe form of nausea and vomiting can lead to extreme dehydration, malnutrition, and hospitalization, posing significant risks to both the mother and the developing fetus.
A breakthrough international study has now identified the genes asociados a las náuseas más severas en el embarazo, providing the first comprehensive genetic map of this disorder. Researchers from the Keck School of Medicine of USC have uncovered ten genes linked to the condition, six of which had never been associated with severe pregnancy nausea before. This discovery shifts the medical understanding of HG from a condition often dismissed as psychological to a documented biological response.
The study, published in Nature Genetics, utilized a genome-wide association study (GWAS) to analyze the DNA of nearly 11,000 women who suffered from HG, comparing them against a massive control group of more than 460,000 individuals. By including diverse populations—including European, Asian, African, and Latina participants—the researchers ensured that the genetic markers identified are relevant across different ethnic backgrounds.
Decoding the Genetic Architecture of HG
The research team, led by Marlena Fejzo, an adjunct clinical professor at the Center for Genetic Epidemiology at the Keck School of Medicine, sought to understand why some women are predisposed to extreme nausea whereas others are not. The study identified a complex interplay of genes that regulate everything from placental development to how the brain processes appetite and hormonal changes.
The findings categorized the identified genes into two groups: those previously linked to pregnancy and a set of entirely new discoveries. The previously known genes—GDF15, GFRAL, IGFBP7, and PGR—are primarily involved in hormonal adaptation and the development of the placenta. However, the study added six new variants to the map: FSHB, TCF7L2, SLITRK1, SYN3, IGSF11, and CDH9.
One of the most striking findings is the role of the TCF7L2 gene. This specific gene is well-documented in medical literature for its association with type 2 diabetes and gestational diabetes. Its emergence in the context of hyperemesis gravídica suggests a potential link between metabolic regulation and the severity of pregnancy nausea, though Fejzo noted that the exact mechanism of how this gene influences HG during pregnancy is still being explored.
Beyond the placenta, the researchers found that several of these genes are involved in the brain’s adaptation process. This suggests that the brain may create powerful, persistent associations between specific foods and the feeling of malaise, leading to the severe food aversions that make nutrition nearly impossible for women with HG.
The Role of GDF15 and Hormonal Sensitivity
Central to this research is the GDF15 hormone. While many women experience a rise in GDF15 during pregnancy, the study suggests that the severity of the nausea is not just about the amount of the hormone present, but rather how sensitive a woman’s body is to it.
According to the researchers, women who have naturally low levels of GDF15 before becoming pregnant may be at a higher risk of developing severe symptoms. Conversely, those with higher baseline concentrations often experience milder nausea. As Fejzo explained, the key lies in the individual’s sensitivity to the hormone, which determines whether the body reacts with mild discomfort or incapacitating vomiting.
This genetic predisposition doesn’t exist in a vacuum. The study also noted that some of the identified genes were linked to other obstetric complications, such as preeclampsia, low birth weight, and shorter pregnancy durations, suggesting that the genetic markers for HG may be part of a broader spectrum of pregnancy-related biological vulnerabilities.
Comparing Genetic Markers in Severe Pregnancy Nausea
| Gene Category | Key Examples | Primary Biological Role |
|---|---|---|
| Previously Linked | GDF15, GFRAL, PGR | Placental development & hormonal adaptation |
| Newly Identified | TCF7L2, FSHB, CDH9 | Metabolism, insulin, and brain adaptation |
| Metabolic Link | TCF7L2 | Associated with Type 2 and Gestational Diabetes |
Moving Toward Personalized Treatment
For decades, the standard of care for HG has been limited. The most common pharmaceutical intervention, Zofran (ondansetron), only provides partial relief for about half of the patients. Because the condition was often misunderstood or attributed to psychological stress, many women suffered without targeted medical support.
The identification of these genes asociados a las náuseas más severas en el embarazo opens the door to precision medicine. By understanding the biological drivers—specifically the GDF15 pathway—scientists can now develop therapies that target the cause rather than just the symptoms.
In a significant step toward clinical application, the Keck School of Medicine of USC has received approval to initiate a clinical trial using metformin. While primarily known as a diabetes medication, metformin has been shown to increase GDF15 levels. Researchers hope to determine if administering this medication preventatively to predisposed women before pregnancy can reduce the risk or severity of hyperemesis gravídica.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Please consult a healthcare provider for diagnosis and treatment of pregnancy-related conditions.
The next critical milestone for this research will be the results of the metformin clinical trials, which aim to prove that modulating GDF15 levels can prevent the onset of hyperemesis gravídica in high-risk women. If successful, this could transform the prenatal care experience for millions of women worldwide.
Do you or a loved one have experience with hyperemesis gravídica? We invite you to share your story and comments in the section below.
